Home
Clinical Trials
Post-Marketing Surveillance o...

Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

NCT ID: NCT01946919

Last Updated: 2022-07-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

18260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cinepazide Maleate Injection is widely used in cerebrovascular disease in china. The safety of the cinepazide, especially the blood system, has not been fully evaluated in Chinese population. In order to improve the rational use of cinepazide, the investigators observe its clinical use in the real world in China, evaluate its safety and clinical benefit in a large Chinese population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Registry of Multimodality Treatment for Brain Arteriovenous Malformation in Mainland China

NCT04572568

Brain Arteriovenous Malformation

RECRUITING

Multi-center Imaging Genetics Studies in China

NCT02681822

Alzheimer Disease Schizophrenia Major Depressive Disorders

UNKNOWN

Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China

NCT04961450

Amyotrophic Lateral Sclerosis Frontotemporal Dementia Motor Neuron Disease

ENROLLING_BY_INVITATION

Treatment Strategies for Unruptured Intracranial Aneurysms in the Chinese Population China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA)

NCT05844163

Unruptured Intracranial Aneurysm

COMPLETED

Evaluation of Brain Health and Surgical Efficacy in Patients With Carotid Artery Stenosis

NCT05848921

Carotid Artery Stenosis Image

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cinepazide was firstly approved in France in 1974, and the formulations are injection and tablet. Products containing cinepazide have been withdrawn in 1990s by the manufacturers because of lacking of demonstrated efficacy and the risk of agranulocytosis in some European countries, such as France, Spain, Italy. In some Aisa countries, it has not been re-registered in Japan in 2000s, and the injection is still used in China and Korea. In china, Cinepazide Maleate Injection was approved by China Food and Drug Administration(CFDA) in 2002, and widely used in cerebrovascular disease. The safety of the Cinepazide, especially the adverse drug reactions in the blood system, has not benn fully evaluated in Chinese population. In this study, clinical pharmacists in selected hospitals will record the clinical use and the adverse drug reactions/ adverse drug events of this injection. This real world study for Cinepazide Maleate Injection with 18000 patients will be conducted from Sep. 2012 to June. 2014.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adverse Drug Reaction Cinepazide Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cinepazide

Inpatient using the cinepazide in department of neurology

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inpatient using the cinepazide in the department of neurology

Exclusion Criteria

* none

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Suodi ZHAI

Suodi ZHAI, Department of Pharmacy, Peking University Third Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.